Home7CA • FRA
add
Camurus AB
Previous close
€40.88
Day range
€40.90 - €40.90
Year range
€19.35 - €51.95
Market cap
27.46B SEK
Avg Volume
2.00
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 374.57M | 39.76% |
Operating expense | 363.03M | 63.65% |
Net income | -15.21M | -216.37% |
Net profit margin | -4.06 | -183.20% |
Earnings per share | -0.27 | -217.39% |
EBITDA | -17.14M | -178.09% |
Effective tax rate | 15.58% | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.19B | 110.39% |
Total assets | 1.91B | 46.14% |
Total liabilities | 414.82M | 33.46% |
Total equity | 1.49B | — |
Shares outstanding | 55.62M | — |
Price to book | 1.52 | — |
Return on assets | -2.80% | — |
Return on capital | -3.47% | — |
Cash Flow
Net change in cash
| (SEK) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -15.21M | -216.37% |
Cash from operations | 30.01M | -33.46% |
Cash from investing | -2.38M | -692.36% |
Cash from financing | 11.29M | 848.91% |
Net change in cash | 35.99M | -21.77% |
Free cash flow | 82.51M | 114.55% |
About
Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap.
Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures. The company provides nanoscale drug-delivery systems for development of high-value therapeutics. Wikipedia
Founded
1991
Website
Employees
213
